Pierre Fabre

Jun 28, 2024

Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA(TM) (vibegron) in overactive bladder.

Jun 21, 2024

Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer

Jun 05, 2024

Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET Alterations

May 21, 2024

Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA

Apr 26, 2024

Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(TM)(vibegron) in overactive bladder syndrome

Mar 01, 2024

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Dec 21, 2020

Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004

Dec 14, 2020

The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention

Nov 09, 2020

Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors